• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Beta Bionics, Inc. - Common Stock (NQ:BBNX)

    27.70 +0.48 (+1.78%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Beta Bionics, Inc. - Common Stock

    Let's uncover which stocks are experiencing notable gaps during today's session.
    The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
    Via Chartmill
    Beta Bionics (BBNX) Q3 2025 Earnings Transcript
    Beta Bionics (BBNX) Q3 2025 Earnings Transcript 
    Via The Motley Fool
    Topics Earnings Supply Chain
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Wondering what's happening in today's after-hours session?
    As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
    Via Chartmill
    Earnings Scheduled For October 28, 2025
     
    Via Benzinga
    Beyond The Numbers: 6 Analysts Discuss Beta Bionics Stock
     
    Via Benzinga
    Earnings Scheduled For July 29, 2025
     
    Via Benzinga
    Beta Bionics Inc (NASDAQ:BBNX) Tops Q3 2025 Revenue Estimates and Raises Full-Year Guidance
    Beta Bionics (BBNX) beat Q3 2025 revenue estimates and raised its full-year guidance. The medical device company reported strong user growth and a narrower-than-expected loss. 
    Via Chartmill
    12 Health Care Stocks Moving In Tuesday's After-Market Session
     
    Via Benzinga
    Demystifying Beta Bionics: Insights From 5 Analyst Reviews
     
    Via Benzinga
    Forecasting The Future: 4 Analyst Projections For Beta Bionics
     
    Via Benzinga
    Beta Bionics (BBNX) Q2 Revenue Soars 54%
    Via The Motley Fool
    Topics Intellectual Property
    Earnings Scheduled For May 6, 2025
     
    Via Benzinga
    Beta Bionics BBNX Q2 2025 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Beta Bionics Inc (NASDAQ:BBNX) Surpasses Q2 2025 Estimates and Raises Full-Year Guidance
    Beta Bionics (BBNX) beats Q2 2025 revenue and EPS estimates, raises full-year guidance. Shares surge 5.7% as iLet Bionic Pancreas and new insulin pump drive growth. 
    Via Chartmill
    Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
    Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
     
    Via Benzinga
    Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
    Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
    Via Benzinga
    Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral
    Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation. 
    Via Stocktwits
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Earnings Scheduled For March 25, 2025
     
    Via Benzinga
    This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
     
    Via Benzinga
    This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
     
    Via Benzinga
    Infinity Natural Resources Valued At $1.3 Billion In Market Debut
    Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3 billion. The listing arrived amid a more fossil fuel-friendly White House... 
    Via Talk Markets
    Topics Energy Stocks / Equities
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.